This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Noridian Notifies Myriad Of Initial Draft Decision To Classify Prolaris(R) As A Non-Covered Service

SALT LAKE CITY, Sept. 24, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that Noridian, the Medicare Administrator for Utah, has notified Myriad of its intent to add the Company's prostate prognostic test, Prolaris®, to its next draft Non-Covered Service LCD (local coverage determination). Noridian will solicit public and provider comment on the Prolaris test before making a final decision.

During the public comment period, Myriad will review the draft LCD with Noridian to underscore the role of the test as a molecular staging diagnostic that guides therapy for prostate cancer patients. Myriad is dedicated to ensuring patients and physicians have access to the critical prognostic information provided by the Prolaris test and therefore will provide additional clarity on how the test is currently being used for medical management of patients with prostate cancer.   

"One of the major challenges in prostate cancer is determining who is at high risk of progression, which has led to the controversy about over-treatment," said E. David Crawford, M.D., distinguished Professor of Surgery, Urology and Radiation Oncology at the University of Colorado. "What is desperately needed is a test that will more accurately determine an individual's prostate cancer malignant potential. I have had experience with the test and have found Prolaris to be a significant step toward enabling the clinician to more confidently advise the patient in making an appropriate medical decision. It is important that patients have access to this cutting edge test to be able to better select appropriate treatment for their prostate cancer."

In four clinical studies on approximately 1500 patients, the Prolaris test was shown to be a highly significant and accurate predictor of the aggressiveness of a man's prostate cancer. Two of the clinical studies demonstrated that the Prolaris test accurately predicted a patient's risk of biochemical recurrence of disease and the other studies predicted ten year survival rate in patients whose prostate cancer was monitored under a watchful waiting approach. Studies were performed on radical prostatectomy, transurethral resection of the prostate (TURP), and biopsy tissue. At diagnosis, Prolaris was the strongest single predictor of prostate cancer specific mortality. Today, the test is available to assist patients and physicians in medical management decisions for both pre-treatment and post-treatment patients. 

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,010.68 -115.44 -0.64%
S&P 500 2,107.39 -13.40 -0.63%
NASDAQ 5,070.0260 -27.95 -0.55%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs